<DOC>
	<DOCNO>NCT00460655</DOCNO>
	<brief_summary>This study confirm superior efficacy GSK1358820 placebo patient equinus deformity associate post-stroke low limb spasticity use Modified Ashworth Scale ( MAS ) ankle score .</brief_summary>
	<brief_title>Study GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity</brief_title>
	<detailed_description>This study confirm superior efficacy GSK1358820 placebo patient equinus deformity associate post-stroke low limb spasticity use Modified Ashworth Scale ( MAS ) ankle score .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Subjects eligible enrollment study must meet following criterion : Patients low limb spasticity least 6 month poststroke present equinus deformity ( plantar flexion ankle ) start doubleblind phase ( Visit 2 ) . Patients MAS ankle score ≥3 start doubleblind phase ( Visit 2 ) . Male female 20 80 year age time informed consent . For male , practice contraception study period eligible . ≥50kg weight start doubleblind phase ( Visit 2 ) . Inpatient outpatient ; however , hospitalization status must remain unchanged doubleblind phase . NOTE : Subjects may hospitalize ≤10 day injection treatment period . Written inform consent subject him/herself . If subject 's signature legible , attendance witness require . A subject eligible inclusion study follow criterion apply : Bilateral hemiplegia quadriplegia . Presence fix contracture ankle ( absence range motion ) . Profound atrophy muscle inject . Previous surgical intervention , phenol block , ethanol block , Muscle Afferent Block ( MAB ) ankle spasticity . Casting study low limb within 3 month prior start doubleblind phase ( Visit 2 ) . Current treatment intrathecal baclofen . Use peripheral muscle relaxant ( dantrolene sodium , suxamethonium chloride , pancuronium bromide , vecuronium bromide , rocuronium bromide ) . Concurrent use antibiotic interfere neuromuscular transmission , aminoglycoside antibiotic ( e.g. , streptomycin sulfate , kanamycin sulfate , gentamicin sulfate , neomycin sulphate , spectinomycin hydrochloride ) , polypeptide antibiotic ( e.g. , polymixin B sulfate ) , lincomycin antibiotic ( e.g. , lincomycin hydrochloride , clindamycin ) , enviomycin sulfate . Previous current botulinum toxin therapy serotype . Diagnosis systemic neuromuscular disorder ( e.g. , myasthenia gravis , LambertEaton syndrome , amyotrophic lateral sclerosis ) . Females pregnant , nursing , may pregnant , plan pregnancy study period . Known allergy hypersensitivity ingredient study medication ( e.g. , human serum albumin ) . Presence psychiatric disorder impairment intellectual function may interfere subject 's ability give inform consent conduct study . Bedridden patient . Presence clinically unstable severe cardiovascular disease . Presence clinically significant severe renal hepatic disease . Infection dermatological condition propose injection site . Previous planned participation another clinical study ( include upper limb spasticity study GSK1358820 ) within 6 month prior start doubleblind phase ( Visit 2 ) . Others investigator sub investigator considers eligible study . Clinically significant severe reduction muscle strength . Angle closure glaucoma preposition ( narrow angle ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Post-Stroke</keyword>
	<keyword>Lower Limb</keyword>
	<keyword>botulinum toxin type A</keyword>
	<keyword>Spasticity</keyword>
</DOC>